Literature DB >> 26403370

Vaxvec: The first web-based recombinant vaccine vector database and its data analysis.

Shunzhou Deng1, Carly Martin2, Rasika Patil2, Felix Zhu2, Bin Zhao3, Zuoshuang Xiang4, Yongqun He5.   

Abstract

A recombinant vector vaccine uses an attenuated virus, bacterium, or parasite as the carrier to express a heterologous antigen(s). Many recombinant vaccine vectors and related vaccines have been developed and extensively investigated. To compare and better understand recombinant vectors and vaccines, we have generated Vaxvec (http://www.violinet.org/vaxvec), the first web-based database that stores various recombinant vaccine vectors and those experimentally verified vaccines that use these vectors. Vaxvec has now included 59 vaccine vectors that have been used in 196 recombinant vector vaccines against 66 pathogens and cancers. These vectors are classified to 41 viral vectors, 15 bacterial vectors, 1 parasitic vector, and 1 fungal vector. The most commonly used viral vaccine vectors are double-stranded DNA viruses, including herpesviruses, adenoviruses, and poxviruses. For example, Vaxvec includes 63 poxvirus-based recombinant vaccines for over 20 pathogens and cancers. Vaxvec collects 30 recombinant vector influenza vaccines that use 17 recombinant vectors and were experimentally tested in 7 animal models. In addition, over 60 protective antigens used in recombinant vector vaccines are annotated and analyzed. User-friendly web-interfaces are available for querying various data in Vaxvec. To support data exchange, the information of vaccine vectors, vaccines, and related information is stored in the Vaccine Ontology (VO). Vaxvec is a timely and vital source of vaccine vector database and facilitates efficient vaccine vector research and development.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bioinformatics; Database; Recombinant vaccine vector; Recombinant vector vaccine; Vaccine; Vaxvec

Mesh:

Substances:

Year:  2015        PMID: 26403370      PMCID: PMC4679550          DOI: 10.1016/j.vaccine.2015.07.113

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  42 in total

1.  Surface-displayed expression of a neutralizing epitope of ApxIIA exotoxin in Saccharomyces cerevisiae and oral administration of it for protective immune responses against challenge by Actinobacillus pleuropneumoniae.

Authors:  Jung-Mi Kim; Dea-Im Jung; Yoo Jeong Eom; Seung-Moon Park; Han-Sang Yoo; Yong-Suk Jang; Moon-Sik Yang; Dae-Hyuk Kim
Journal:  Biosci Biotechnol Biochem       Date:  2010-07-07       Impact factor: 2.043

2.  Induction of specific cytotoxic lymphocytes in mice vaccinated with Brucella abortus RB51.

Authors:  Y He; R Vemulapalli; A Zeytun; G G Schurig
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

3.  Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51.

Authors:  R Vemulapalli; Y He; S Cravero; N Sriranganathan; S M Boyle; G G Schurig
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

4.  Biological properties of RB51; a stable rough strain of Brucella abortus.

Authors:  G G Schurig; R M Roop; T Bagchi; S Boyle; D Buhrman; N Sriranganathan
Journal:  Vet Microbiol       Date:  1991-07       Impact factor: 3.293

5.  Reduced cerebral infection of Neospora caninum in BALB/c mice vaccinated with recombinant Brucella abortus RB51 strains expressing N. caninum SRS2 and GRA7 proteins.

Authors:  Ramesh Vemulapalli; Neelima Sanakkayala; Jatinder Gulani; Gerhardt G Schurig; Stephen M Boyle; David S Lindsay; Nammalwar Sriranganathan
Journal:  Vet Parasitol       Date:  2007-07-24       Impact factor: 2.738

6.  Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development.

Authors:  Yongqun He; Zuoshuang Xiang; Harry L T Mobley
Journal:  J Biomed Biotechnol       Date:  2010-07-04

7.  A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.

Authors:  Yoshimi Tsuda; Patrizia Caposio; Christopher J Parkins; Sara Botto; Ilhem Messaoudi; Luka Cicin-Sain; Heinz Feldmann; Michael A Jarvis
Journal:  PLoS Negl Trop Dis       Date:  2011-08-09

Review 8.  Emerging vaccine informatics.

Authors:  Yongqun He; Rino Rappuoli; Anne S De Groot; Robert T Chen
Journal:  J Biomed Biotechnol       Date:  2011-06-15

9.  BBP: Brucella genome annotation with literature mining and curation.

Authors:  Zuoshuang Xiang; Wenjie Zheng; Yongqun He
Journal:  BMC Bioinformatics       Date:  2006-07-16       Impact factor: 3.169

10.  Genome-wide prediction of vaccine targets for human herpes simplex viruses using Vaxign reverse vaccinology.

Authors:  Zuoshuang Xiang; Yongqun He
Journal:  BMC Bioinformatics       Date:  2013-03-08       Impact factor: 3.169

View more
  1 in total

1.  Integrative representations and analyses of vaccine-induced intended protective immunity and unintended adverse events using ontology-based and theory-guided approaches.

Authors:  Yongqun He; Edison Ong; Jiangan Xie
Journal:  Glob Vaccines Immunol       Date:  2016-05-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.